Rigel Pharmaceuticals Stock Short Ratio
| RIGL Stock | USD 0.96 0.01 1.35% |
Rigel Pharmaceuticals fundamentals help investors to digest information that contributes to Rigel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rigel Stock. The fundamental analysis module provides a way to measure Rigel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rigel Pharmaceuticals stock.
Rigel | Short Ratio |
Rigel Pharmaceuticals Company Short Ratio Analysis
Rigel Pharmaceuticals' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Rigel Pharmaceuticals Short Ratio | 2.88 X |
Most of Rigel Pharmaceuticals' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rigel Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rigel Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Rigel Pharmaceuticals is extremely important. It helps to project a fair market value of Rigel Stock properly, considering its historical fundamentals such as Short Ratio. Since Rigel Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rigel Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rigel Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Rigel Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Rigel Pharmaceuticals has a Short Ratio of 2.88 times. This is 26.15% lower than that of the Biotechnology sector and 61.13% lower than that of the Health Care industry. The short ratio for all United States stocks is 28.0% higher than that of the company.
Rigel Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rigel Pharmaceuticals' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics of similar companies.Rigel Pharmaceuticals is currently under evaluation in short ratio category among related companies.
Rigel Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Rigel Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rigel Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rigel Pharmaceuticals' value.| Shares | Assenagon Asset Management Sa | 2024-03-31 | 2 M | Cm Management, Llc | 2023-12-31 | 1.7 M | Macquarie Group Ltd | 2023-12-31 | 1.6 M | Northern Trust Corp | 2023-12-31 | 1.5 M | Gsa Capital Partners Llp | 2023-12-31 | 1.4 M | Renaissance Technologies Corp | 2023-12-31 | 1.3 M | Sphera Funds Management Ltd. | 2023-12-31 | 1.2 M | Goldman Sachs Group Inc | 2023-12-31 | 1 M | Ubs O'connor Llc | 2023-12-31 | 899.3 K | Armistice Capital, Llc | 2023-12-31 | 17.1 M | Blackrock Inc | 2023-12-31 | 15.2 M |
Rigel Fundamentals
| Return On Equity | -6.99 | ||||
| Return On Asset | -0.0791 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 221.97 M | ||||
| Shares Outstanding | 175.41 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 63.84 % | ||||
| Number Of Shares Shorted | 5.67 M | ||||
| Price To Earning | (5.63) X | ||||
| Price To Book | 31.64 X | ||||
| Price To Sales | 1.82 X | ||||
| Revenue | 116.88 M | ||||
| Gross Profit | 53.72 M | ||||
| EBITDA | (16.98 M) | ||||
| Net Income | (25.09 M) | ||||
| Cash And Equivalents | 81.64 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 60.58 M | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | (0.18) X | ||||
| Cash Flow From Operations | (5.74 M) | ||||
| Short Ratio | 2.88 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 4.53 | ||||
| Number Of Employees | 147 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 170.04 M | ||||
| Total Asset | 117.22 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46 M | ||||
| Current Asset | 129.02 M | ||||
| Current Liabilities | 33.8 M | ||||
| Net Asset | 117.22 M |
About Rigel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rigel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rigel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rigel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:Check out Rigel Pharmaceuticals Piotroski F Score and Rigel Pharmaceuticals Altman Z Score analysis. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.Note that the Rigel Pharmaceuticals information on this page should be used as a complementary analysis to other Rigel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Rigel Stock analysis
When running Rigel Pharmaceuticals' price analysis, check to measure Rigel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rigel Pharmaceuticals is operating at the current time. Most of Rigel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rigel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rigel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rigel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Rigel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share (0.11) | Revenue Per Share 0.684 | Quarterly Revenue Growth 0.133 | Return On Assets (0.08) |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.